|
Exelixis, Inc. - Comparative Business Analysis Snapshot
Business Description
Exelixis, Inc.. The Group's principal activity is to develop innovative therapies for cancer and other serious diseases. Its pharmaceutical programs focuses on discovery and development of small molecule drugs for cancer. The Gruoup has built a multidisciplinary, integrated research and development platform that supports the complex, iterative nature of drug discovery, translational research and clinical development. Its first-generation anticancer product candidates in our clinical pipeline are Spectrum Selective Kinase Inhibitors, that have been optimized for balanced potency, specificity, tolerability and pharmacologic parameters. It operates in the United States.
Competitor Analysis
This analysis compares Exelixis, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
